DeepQure Strengthens Clinical Leadership with Former SoniVie Executive Appointment

SEOUL, South Korea, Sept. 3, 2025 /PRNewswire/ — DeepQure, a company at the forefront of transforming hypertension treatment, has named Jason G. Jones as its new Global Vice President of Clinical & Regulatory Affairs. Jason’s appointment represents a strategic decision by DeepQure to enhance its leadership in clinical affairs. His extensive experience, particularly from his time at SoniVie, aligns with DeepQure’s mission to push boundaries in hypertension management.

Jason’s expertise is a valuable addition to DeepQure’s team. His proven track record in clinical and regulatory affairs brings a new dynamic to the company’s approach to tackling hypertension challenges. The appointment of a seasoned industry leader like Jason is a clear indication of DeepQure’s commitment to driving innovation and excellence in the treatment of hypertension.

DeepQure’s CEO expressed excitement about welcoming Jason to the team, highlighting the importance of having a strong clinical leader to steer the company’s efforts towards groundbreaking advancements in hypertension care. With Jason on board, DeepQure aims to accelerate its clinical research initiatives and regulatory strategies for developing innovative solutions in hypertension treatment.

Jason shared his enthusiasm about joining DeepQure and embracing the opportunity to contribute to the company’s vision of redefining hypertension treatment. He emphasized the potential for transformative impact through a patient-centric approach and collaboration with regulatory authorities to bring new, effective therapies to those in need.

The appointment of Jason G. Jones as Global Vice President of Clinical & Regulatory Affairs underscores DeepQure’s commitment to assembling a world-class team of experts dedicated to revolutionizing hypertension care. Jason’s leadership is expected to drive advancements in clinical trials, regulatory processes, and ultimately, patient outcomes in the realm of hypertension management.

As DeepQure continues its mission to pioneer innovative therapies for hypertension, Jason’s appointment signifies a significant milestone in the company’s journey. His strategic vision and expertise are set to shape the future direction of DeepQure’s clinical and regulatory initiatives, propelling the company towards achieving new standards of excellence in hypertension treatment.